A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

NCT04809220 on ClinicalTrials.gov · last registry update 2024-05-22

Finished 1 October 2022, after enrolling 591 people. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26. dulaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 591
Started: 2021-04-13
Primary completion: 2022-10-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26

Conditions studied

Diabetes Mellitus · Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders · Metabolic Disease · Endocrine System Diseases · Hypoglycemic Agents · Type 2 Diabetes Mellitus (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.